Companies › Zenas BioPharma (USA)
2 active drug programs in 6 registered trials: 4 Phase 3, 2 Phase 2; Neurology, Hematology, Immunology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Obexelimab B-lymphocyte antigen CD19 inhibitor; Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor | CD19, FCGR2B | Phase 3 | Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis; Systemic Lupus Erythematosus | Dec 2026 |
| Orelabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Secondary Progressive Multiple Sclerosis; Multiple Sclerosis (MS) Primary Progressive | Jun 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06564311 | Obexelimab | Phase 2 | Relapsing Multiple Sclerosis | Neurology | Aug 2025 |
| NCT05786573 | Obexelimab | Phase 3 | Warm Autoimmune Hemolytic Anemia | Hematology | Jun 2026 |
| NCT06559163 | Obexelimab | Phase 2 | Systemic Lupus Erythematosus | Immunology | Dec 2026 |
| NCT05662241 | Obexelimab | Phase 3 | IgG4 Related Disease | Other | Feb 2029 |
| NCT07299019 | Orelabrutinib | Phase 3 | Secondary Progressive Multiple Sclerosis | Neurology | Jun 2030 |
| NCT07067463 | Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive | Neurology | Jun 2030 |
Cash and short-term investments of $647m on 2026-09-30; operating cash outflow about $256m a year; runway about 30 months at that burn, to Apr 2029; 2 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech AstraZeneca Sanofi Roche Allogene Therapeutics Miltenyi Biomedicine Merck & Co. (MSD) BeOne Medicines
Cartesian Therapeutics COMPASS Pathways Immunovant Sciences Vor Biopharma Evommune
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.